NCT02033668 - Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 22, 2014

Primary Completion Date

July 15, 2014

Study Completion Date

July 15, 2014

Conditions

Atrophy, Geographic

Interventions

DRUG

GSK933776 for SQ administration

Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks

DRUG

GSK933776 for IM administration

Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose

DRUG

GSK933776 for IV administration

Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour

Trial Locations (1)

66211

GSK Investigational Site, Overland Park